Changes in practice patterns affecting in-hospital and post-discharge survival among ACS patients

Manfred Stommel, Ade Olomu, Margaret Holmes-Rovner, William Corser, Joseph C Gardiner, Manfred Stommel, Ade Olomu, Margaret Holmes-Rovner, William Corser, Joseph C Gardiner

Abstract

Background: Adherence to clinical practice guidelines for the treatment of specific illnesses may result in unexpected outcomes, given that multiple therapies must often be given to patients with diverse medical conditions. Yet, few studies have presented empirical evidence that quality improvement (QI) programs both change practice by improving adherence to guidelines and improve patient outcomes under the conditions of actual practice. Thus, we focus on patient survival, following hospitalization for acute coronary syndrome in three successive patient cohorts from the same community hospitals, with a quality improvement intervention occurring between cohorts two and three.

Methods: This study is a comparison of three historical cohorts of Acute Coronary Syndrome (ACS) patients in the same five community hospitals in 1994-5, 1997, 2002-3. A quality improvement project, the Guidelines Applied to Practice (GAP), was implemented in these hospitals in 2001. Study participants were recruited from community hospitals located in two Michigan communities during three separate time periods. The cohorts comprise (1) patients enrolled between December 1993 and April 1995 (N = 814), (2) patients enrolled between February 1997 and September 1997 (N = 452), and (3) patients enrolled between January 14, 2002 and April 13, 2003 (N = 710). Mortality data were obtained from Michigan's Bureau of Vital Statistics for all three patient cohorts. Predictor variables, obtained from medical record reviews, included demographic information, indicators of disease severity (ejection fraction), co-morbid conditions, hospital treatment information concerning most invasive procedures and the use of ace-inhibitors, beta-blockers and aspirin in the hospital and as discharge recommendations.

Results: Adjusted in-hospital mortality showed a marked improvement with a HR = 0.16 (p < 0.001) comparing 2003 patients in the same hospitals to those 10 years earlier. Large gains in the in-hospital mortality were maintained based on 1-year mortality rates after hospital discharge.

Conclusion: Changes in practice patterns that follow recommended guidelines can significantly improve care for ACS patients. In-hospital mortality gains were maintained in the year following discharge.

Figures

Figure 1
Figure 1
Unadjusted Survival Curves Comparing Three Patient Cohorts from the Same Hospitals during Index Hospitalization.
Figure 2
Figure 2
Unadjusted Survival Curves Comparing Three Patient Cohorts from the Same Hospitals Starting with Hospital Discharge to One Year After Hospital Admission.

References

    1. Mehta RH, Montoye CK, Gallogly BA, Baker P, Blount A, Faul J, Roychoudhury C, Borzak S, Fox S, Franklin M, Freundl M, Kline-Rogers E, LaLonde T, Orza M, Parrish R, Satwicz M, Smith MJ, Sobotka P, Winston S, Riba AA, Eagle KA. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269–76. doi: 10.1001/jama.287.10.1269.
    1. Eagle KA, Gallogly M, Mehta RH, Baker PL, Blount A, Freundl M, Orza MJ, Parrish R, Riba AL, Montoye CK. Taking the National Guideline for Care of Acute Myocardial Infarction to the Bedside. Jt Comm J Qual Improv. 2002;28:5–19.
    1. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Azevum A, Flather MD, Granger CB, Erickson S, White K, Steg PG. Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am J Med. 2004;117:73–81. doi: 10.1016/j.amjmed.2003.12.041.
    1. Watson RE, Stein AD, Dwamena FC, Kroll J, Mitra R, McIntosh BA, Vasilenko P, Holmes-Rovner MM, Chen Q, Kupersmith J. Do race and gender influence the use of invasive procedures? J Gen Intern Med. 2001;16:227–34. doi: 10.1046/j.1525-1497.2001.016004227.x.
    1. Barber K, Stommel M, Kroll J, Holmes-Rovner MM, McIntosh BA. Cardiac rehabilitation for community-based patients with myocardial infarction: Factors predicting discharge recommendation and participation. J Clin Epi. 2001;54:1025–30. doi: 10.1016/S0895-4356(01)00375-4.
    1. Dwamena FC, El Tamimi H, Watson RE, Kroll J, Stein AD, McLane A, Holmes-Rovner MM, McIntosh BA, Kupersmith J. The use of angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction in community hospitals. Michigan State University Inter-Institutional Collaborative Heart (MICH) Study Group. Clin Cardiol. 2000;23:341–6.
    1. Census Bureau. County Population Datasets. 2006.
    1. Olomu AB, Watson RE, Siddiqi AE, Dwamena FC, McIntosh B, Vasilenko P, Kupersmith J, Holmes-Rovner MM. Changes in rates of beta-blocker use in community hospital patients with acute myocardial infarction. J Gen Intern Med. 2004;19:999–1004. doi: 10.1111/j.1525-1497.2004.30062.x.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validity. J Chron Dis. 1987;40:373–83. doi: 10.1016/0021-9681(87)90171-8.
    1. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: John Wi, Mark DBley & Sone, Inc; 2002.
    1. Grambsch PM, Thernau TM. Proportional hazard tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–26. doi: 10.2307/2337123.
    1. Harrel FE, Lee KA, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>;2-4.
    1. Centers for Disease Control and Prevention. Health, United States, 2005. Hyattsville, MD: DHHS; 2005.
    1. Silvet H, Spencer F, Yarzebski J, Lessard D, Gore JM, Goldberg RJ. Communitywide trends in the use and outcomes associated with β-blockers in patients with acute myocardial infarction. Arch Intern Med. 2003;163:2175–83. doi: 10.1001/archinte.163.18.2175.
    1. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol. 1998;82:731–6. doi: 10.1016/S0002-9149(98)00540-2.
    1. Anonymous Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol. 2000;35:1122–9. doi: 10.1016/S0735-1097(00)00533-7.
    1. Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramirez JA. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004;43:1743–51. doi: 10.1016/j.jacc.2003.08.065.
    1. Yan AT, Yan RT, Tan M, Eagle KA, Granger CB, Dabbous OH, Fitchett D, Grima E, Langer A, Goodman S. In-hospital Revascularization and One-Year Outcome of Acute Coronary Syndrome Patients Stratified by the GRACE Risk Score. Amer J Cardiol. 2005;96:913–6. doi: 10.1016/j.amjcard.2005.05.046.
    1. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248–54.
    1. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175–9. doi: 10.1016/S0140-6736(89)91200-2.
    1. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340:1421–5. doi: 10.1016/0140-6736(92)92619-Q.
    1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E. The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–19. doi: 10.1056/NEJM199610033351401.
    1. Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiodorek FT, Belder R. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med. 2004;164:40–4. doi: 10.1001/archinte.164.1.40.
    1. Johnson D, Jin Y, Quan H, Cujec B. Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Coll Cardiol. 2003;42:1438–45. doi: 10.1016/S0735-1097(03)01058-1.
    1. Lappé JM, Muhlestein JB, Lappé DL, Badger RS, Bair TL, Brockman R, French TK, Hofmann LC, Horne BD, Kralick-Goldberg S, Nicponski N, Orton JA, Pearson RR, Renlund DG, Rimmasch H, Roberts C, Anderson JL. Improvements in 1-year cardiovascular clinical outcomes associated with hospital-based discharge medication program. Ann Intern Med. 2004;141:446–53.
    1. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med. 2004;141:102–12.
    1. Goldberg RJ, Gurwitz JH. Disseminating the results of clinical trials to community-based practitioners: is anyone listening? Am Heart L. 1999;137:4–7. doi: 10.1016/S0002-8703(99)70453-9.
    1. Bhatt DL, Topol EJ. Percutaneous coronary intervention for patients with prior bypass surgery: therapy in evolution. Am J Med. 2000;108:176–7. doi: 10.1016/S0002-9343(99)00399-X.
    1. Daneman N, Austin PC, Tu JV. Investigating the determinants of decreasing postmyocardial infarction mortality: an analysis of in-hospital data from 1992 and 1997. Can J Cardiol. 2001;17:771–6.
    1. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, Frederick PD, Every N. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056–63. doi: 10.1016/S0735-1097(00)00996-7.
    1. Borkon AM, Muehlebach GF, House J, Marso SP, Spertus JA. A comparison of the recovery of health status after percutaneous coronary intervention and coronary artery bypass. Ann Thorac Surg. 2002;74:1526–30. doi: 10.1016/S0003-4975(02)04063-8.
    1. Frilling B, Schiele R, Gitt AK, Zahn R, Schneider S, Glunz H-G, Gieseler U, Jagodzinski E, Senges J. Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: results from the MITRA study. Am Heart J. 2004;148:306–11. doi: 10.1016/j.ahj.2004.01.027.
    1. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Carig AS, Gold JA, Krumholz HM, Vogel RA. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509–14. doi: 10.1001/jama.273.19.1509.
    1. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499–510. doi: 10.1161/01.CIR.0000154568.43333.82.
    1. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision-making. JAMA. 2000;284:835–42. doi: 10.1001/jama.284.7.835.
    1. O'Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, Marciniak TA, Wennberg JE. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA. 1999;281:627–33. doi: 10.1001/jama.281.7.627.
    1. Guadagnoli E, Landrum MB, Normand SL, Ayanian JZ, Garg P, Hauptman PJ, Ryan TJ, McNeil BJ. Impact of underuse, overuse, and discretionary use on geographic variation in the use of coronary angiography after acute myocardial infarction. Med Care. 2001;39:446–58. doi: 10.1097/00005650-200105000-00005.
    1. Lloyd-Jones DM, Camargo CA, Allen LA, Giugliano RP, O'Donnell CJ. Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction. Am J Cardiol. 2003;92:1155–9. doi: 10.1016/j.amjcard.2003.07.022.
    1. Gardner SC, Grunwald GK, Rumsfeld JS, Mackenzie T, Gao D, Perlin JB, McDonald G, Shroyer AL. Risk factors for intermediate-term survival after coronary artery bypass grafting. Ann Thorac Surg. 2001;72:2033–7. doi: 10.1016/S0003-4975(01)03217-9.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel